Biological Evaluation of Medical Devices: Essential Standards for Safe and Scalable Health Care Solutions

Ensuring the safety of medical devices is critical—both for protecting patients and for helping businesses thrive in a competitive global health care market. The biological evaluation of devices is a cornerstone in this process, making adherence to relevant international standards essential for productivity, trust, and regulatory approval. In this article, we break down the three foundational standards governing the biological evaluation of medical devices—SIST EN ISO 10993-1:2009, SIST EN ISO 10993-1:2010/AC:2010, and SIST EN ISO 10993-1:2021—demystifying their requirements and explaining how businesses can leverage compliance for increased security, productivity, and sustainable growth.

Overview / Introduction

The health care industry is driven by innovation in medical devices, from simple wound dressings to advanced implantable devices. However, with innovation comes the responsibility to ensure that every product introduced to the market is safe for its intended use, especially concerning its biological impact on the human body. This is why standards such as ISO 10993-1 and its European (EN) and Slovenian (SIST) adaptations are not just regulatory requirements—they're strategic assets that enable organizations to:

• Ensure device safety and biocompatibility
• Optimize product development and risk management
• Facilitate market access and compliance with regulations
• Build global consumer trust

In this comprehensive guide, you’ll learn what each of these three standards covers, the key requirements for businesses, practical implications for implementation, and why adopting them is the key to scaling operations safely and responsibly.

Detailed Standards Coverage

SIST EN ISO 10993-1:2009 – The Foundation of Biological Evaluation

Biological evaluation of medical devices - Part 1: Evaluation and testing (ISO 10993-1:2003)

The SIST EN ISO 10993-1:2009 standard represents the foundational approach to the biological evaluation of medical devices. Introduced to align medical device manufacturers with the stringent demands of European directives, it provides the basic structure for categorizing and testing medical devices based on their contact with the human body.

Scope and Core Principles

This standard outlines:

• General principles governing biological evaluation
• Categorization of devices based on nature and duration of body contact
• Selection of appropriate tests for various types of devices
• Exclusion of devices that do not come into contact with the body

It emphasizes a risk-based and systematic assessment process, where the goal is not only to comply with regulations but to proactively minimize potential biological hazards that could arise from materials or device design.

Key Requirements

The standard requires manufacturers to:

• Choose materials fit for purpose, considering chemical, toxicological, and physical properties
• Assess the potential effects of additives, contaminants, leachables, and degradation products
• Plan and document all biological evaluation activities, led by qualified personnel
• Reassess device biocompatibility upon any significant change in materials, manufacturing, or intended use

Practical Application

Device developers must use a structured program of assessment, including both in vitro (laboratory-based) and, where necessary, in vivo (animal or clinical) testing, while minimizing the use of animals. The standard provides a matrix for grouping devices by contact type and duration (e.g., transient, short-term, long-term), guiding which biological tests are optimal for each category.

Key highlights:

• Provides the original, structured “matrix approach” for test selection
• Emphasizes fitness for purpose throughout the device life cycle
• Supports both regulatory compliance and continuous improvement

Access the full standard:View SIST EN ISO 10993-1:2009 on iTeh Standards

SIST EN ISO 10993-1:2010/AC:2010 – Integrating Risk Management

Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process - Technical Corrigendum 1 (ISO 10993-1:2009/Cor 1:2010)

The SIST EN ISO 10993-1:2010/AC:2010 is a technical corrigendum to the previous edition, refining the requirements to better integrate biological evaluation within a comprehensive risk management framework. This aligns the standard more closely with modern principles of medical device risk management, as codified in ISO 14971.

Expanded Scope

Significant updates include:

• Mandating integration of biological evaluation into the organization’s overall risk management process
• Detailed guidance on how to evaluate existing data, identify data gaps, and specify additional investigations based on risk analysis
• Emphasis on assessing devices based on intended contact with the body and user (expanding scope to occupational health)

New and Enhanced Requirements

The corrigendum makes clear:

• Data from various sources must be reviewed as part of risk management
• A gap analysis is necessary to identify missing or insufficient data
• Additional biological testing must be justified and selected to address identified risks
• Excludes devices/materials with no direct/indirect patient contact
• Aligns its approach with the essential requirements of major European directives

Practical Implications

Organizations are expected to:

• Systematically analyze biological risks alongside other device hazards (mechanical, chemical)
• Maintain detailed documentation of every risk assessment step
• Link test selection and depth to the results of risk analysis, avoiding unnecessary or redundant testing

Key highlights:

• Directly links biological evaluation with ISO 14971 risk management
• Promotes systematic identification of data gaps and focused new testing
• Encourages continuous, lifecycle-oriented risk assessment

Access the full standard:View SIST EN ISO 10993-1:2010/AC:2010 on iTeh Standards

SIST EN ISO 10993-1:2021 – The Modern Global Framework

Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process (ISO 10993-1:2018, including corrected version 2018-11)

The latest edition, SIST EN ISO 10993-1:2021, fully embeds the biological evaluation process within risk management, reflecting the latest scientific advances, regulatory expectations, and technical refinements. This modern standard is now the definitive reference for ensuring biological safety and market access for all classes of medical devices in Europe and globally.

Comprehensive Scope

This edition applies to:

• All device types (active, non-active, implantable, non-implantable)
• Direct and indirect patient contact (including devices meant to protect users like gloves and masks)
• Evaluation of devices/materials for all exposures, durations, and routes

Notably, it introduces detailed provisions for:

• Evaluating risks arising from device change over time (aging, degradation)
• Assessing biological impact from potential device/component breakage
• Considering nanomaterials, absorbable materials, and gas pathways

Advanced Requirements

Organizations must now:

• Conduct thorough data gathering (physical, chemical, and biological) for every device
• Identify and address data gaps through targeted testing based on risk analysis
• Apply biocompatibility matrices and structured literature review
• Follow updated risk assessment methodologies for new/emerging hazards

New Features and Guidance

• Annexes detail how to select endpoints for assessment and conduct evaluations within a risk management context
• Guidance for minimizing the use of animal testing by leveraging high-quality in vitro and chemical characterization
• References new global standards for special applications (e.g., breathing gas pathways)

Key highlights:

• World-class, harmonized blueprint for biological evaluation and regulatory compliance
• Addresses modern device technologies, complex materials, and evolving risks
• Facilitates rapid, scalable market access and sustainable compliance programs

Access the full standard:View SIST EN ISO 10993-1:2021 on iTeh Standards

Industry Impact & Compliance

The significance of the ISO 10993-1 standards suite for the health care industry cannot be overstated. Regulation is not the only incentive—adoption drives competitive advantage and operational excellence.

Business Benefits

• Global Market Access: Compliance with these standards is often mandatory to meet EU Medical Device Regulation (MDR), US FDA, and other major health authority requirements.
• Increased Safety & Trust: Systematic biological evaluation ensures devices are safe by minimizing patient and user risk, preventing recalls, and fostering confidence.
• Productivity & Cost Efficiency: Integrating risk-based evaluation into product development streamlines testing, avoids duplication, and enables resource-efficient innovation.
• Scalability: Standardized, systematic approaches support rapid development and regulatory submission for device portfolios, even as organizations grow.

Compliance Requirements

• Fully document biological evaluation and risk assessment activities
• Use scientifically valid methods for selecting, executing, and interpreting tests
• Maintain traceability and clear records for all decision points and results
• Continuously monitor and re-evaluate devices as part of post-market surveillance

Risks of Non-Compliance

• Regulatory rejection (including denial or withdrawal of market approval)
• Increased liability and risk of product recalls
• Loss of consumer and stakeholder trust
• Resource inefficiency and competitive disadvantage

Implementation Guidance

Adopting ISO 10993-1 and its updates is very achievable—especially with a structured approach and the right resources.

Common Approaches

1. Establish a Cross-Functional Team: Involve R&D, Quality, Regulatory, and Clinical experts in planning the biological evaluation strategy.
2. Map Device Portfolio: Categorize all current and new devices by type and intended use; identify risk categories and applicable standards.
3. Conduct Gap Analysis: Review all available biological, chemical, and clinical data. Identify missing information and the need for new testing.
4. Integrate Risk Management: Make biological evaluation an explicit part of your ISO 14971-compliant risk management process.
5. Select Tests Strategically: Leverage the standards’ matrices to focus on tests that are scientifically necessary, avoiding over-testing.
6. Document Everything: Maintain meticulous records, justifications, literature reviews, and test reports for both regulators and internal learning.

Best Practices

• Stay Current: Monitor updates to the ISO 10993 series and relevant regional adaptations.
• Invest in Staff Training: Ensure personnel are well-versed in biological evaluation methods and regulatory expectations.
• Partner with Experts: Work with accredited laboratories and consultants experienced in medical device biocompatibility.
• Leverage In Vitro Data: When possible, use validated in vitro data or chemical characterization to reduce animal testing.
• Continuous Review: Reassess device biocompatibility whenever materials, processes, or intended use changes.

Helpful Resources

• The iTeh Standards health care collection for full-text and related publications
• Regulatory authorities’ guidance documents (EU MDR, FDA guidance)
• Accredited testing laboratories and ISO 10993 expert consultants

Conclusion / Next Steps

The biological evaluation of medical devices is a multidisciplinary process at the heart of safe, effective, and innovative health care. As the field evolves, these leading standards—SIST EN ISO 10993-1:2009, SIST EN ISO 10993-1:2010/AC:2010, and SIST EN ISO 10993-1:2021—remain the definitive guides for global manufacturers, regulators, and health care providers. By adopting these standards, organizations not only achieve compliance but unlock greater productivity, build lasting security for their brand, and position themselves for scalable, sustainable growth.

Key Takeaways:

• Regulatory compliance with biological evaluation standards is non-negotiable for market access and patient safety.
• The integration of risk management and continuous data evaluation streamlines development and fosters innovation.
• Implementing these standards with best practices offers a pathway to greater organizational efficiency, global competitiveness, and trust.

Ready to take your medical device safety program to the next level?

Explore the latest international standards, implement robust evaluation processes, and stay ahead of regulatory requirements with resources available at iTeh Standards. Protect patients, support business growth, and build tomorrow’s health care solutions—starting with world-class standards today.